Akcea submits NDA for volanesorsen to treat familial chylomicronemia syndrome

Akcea Therapeutics Inc. (NASDAQ:AKCA) submitted an NDA to FDA for volanesorsen (IONIS-APOCIIIRx, ISIS 304801) to treat familial chylomicronemia syndrome (FCS). An MAA for the apolipoprotein C-III (APOCIII; APOC3) antisense inhibitor is under EMA review for the indication...